Delivering clinical supplies into the European Union and United Kingdom requires rigorous
oversight from a QP to ensure every batch meets regulatory, GMP, and trial-specific requirements. Yet, many
sponsors face preventable delays, often due to incomplete documentation, limited supply chain visibility, or
late communication of changes. This paper breaks down the core responsibilities of the QP, explains how
European Union and United Kingdom expectations differ, and share practical steps sponsors can take to
streamline the certification process. Readers will learn how to prepare audit-ready documentation, avoid
common pitfalls that extend release timelines, and build efficient collaborations with QPs to keep studies
moving without interruption.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.